<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539431</url>
  </required_header>
  <id_info>
    <org_study_id>ICP_glioma_001</org_study_id>
    <nct_id>NCT04539431</nct_id>
  </id_info>
  <brief_title>Glioma Brain Tumours - E12513 - SensiScreen Glioma</brief_title>
  <official_title>Sensitive Diagnosis, Prognosis and Treatment Planning on Open Platform of Glioma Brain Tumours - E12513 - SensiScreen Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ente Ospedaliero Cantonale, Bellinzona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istituto Cantonale di Patologia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Neurocenter of Southern Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ente Ospedaliero Cantonale, Bellinzona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Validation of a new platform for the molecular characterization of patients affected by&#xD;
      glioma. The new platform includes a series of faster, less expensive real-time PCR&#xD;
      methodologies that, in comparison to standard analyses (DS, MS-PCR), are also characterized&#xD;
      by higher sensitivity and consequently can be able to identify mutations in ctDNA extracted&#xD;
      from liquid biopsies as well. The development of these assays will allow the analysis of&#xD;
      molecular markers alteration even in liquid biopsies, providing a less invasive sampling than&#xD;
      tissue biopsies, a procedure that sometimes is characterized by side effects or that allow&#xD;
      the collection of few tissues for the histological and molecular diagnosis.&#xD;
&#xD;
      This study will not interfere with the patients routine treatment pathway and there will be&#xD;
      no deviation from the standard of care: the molecular characterization of the tissues will be&#xD;
      performed according to the standard diagnostic routine using the currently approved&#xD;
      methodologies. For the retrospective study, it will be used the left-over DNA. For the&#xD;
      cohort, that includes the collection and the subsequent analysis of liquid biopsies&#xD;
      (prospective study), blood and CSF will be sampled during surgery.&#xD;
&#xD;
      The mutations in the molecular markers will be analyzed in tissue as well as in plasma and&#xD;
      CFS samples by the new real-time based assays. Then, the qualitative and quantitative values&#xD;
      obtained on liquid biopsies with the new methodology will be compared to the results of the&#xD;
      standard methodologies already obtained, for diagnostic routine, on surgical tissue samples&#xD;
      of the same patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstration that the new methodology improves the features</measure>
    <time_frame>2 hours</time_frame>
    <description>Demostrate that are found at least the same number of mutations in comparison with respect to standard tests</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Retrospective</arm_group_label>
    <description>The cases with glioma will be identified in the databases of hospital, the material will be preliminarily evaluated in order to see if there is sufficient tissue left for analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective</arm_group_label>
    <description>A blood sample for molecular analyses will be collected in all the cases, CSF samples will be taken only if recommended by the normal surgical routine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>validation of new technologies</intervention_name>
    <description>Development of a new molecular assay on tissue as well as on liquid biopsies (plasma and CSF), based on a single, open, real-time PCR platform with unprecedented sensitivity</description>
    <arm_group_label>Prospective</arm_group_label>
    <arm_group_label>Retrospective</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Liquid biopsies, tissue block, blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients affected by suspected glioma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Retrospective Cohort&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with available tissue material or with available molecular data concerning the&#xD;
             tissue biopsy obtained during surgery and analyzed for diagnosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Insufficient amount of tumor cells in the tissue biopsy for the molecular&#xD;
             characterization&#xD;
&#xD;
          -  Inability to consent and follow the procedures of the study (for alive patients)&#xD;
&#xD;
        Prospective Cohort&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years old&#xD;
&#xD;
          -  Affected by suspected glioma and requiring surgery&#xD;
&#xD;
          -  Patient with available tissue material or with available molecular data concerning the&#xD;
             tissue biopsy obtained during surgery and analyzed for diagnosis&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Insufficient amount of tumor cells in the tissue biopsy for the molecular&#xD;
             characterization&#xD;
&#xD;
          -  Inability to consent and follow the procedures of the study&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milo Frattini, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Pathology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Milo Frattini, PhD</last_name>
    <phone>+ 41 (0)91 816 08 05</phone>
    <email>milo.frattini@eoc.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Pathology Ente Ospedaliero Cantonale</name>
      <address>
        <city>Locarno</city>
        <zip>6600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Milo Frattini, PhD</last_name>
      <phone>+ 41 (0)91 816 08 05</phone>
      <email>milo.frattini@eoc.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ente Ospedaliero Cantonale, Bellinzona</investigator_affiliation>
    <investigator_full_name>Milo Frattini</investigator_full_name>
    <investigator_title>Head, Molecular Pathology Service</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

